NCT05764590View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

August 25, 2023

Study Completion Date

September 14, 2023

Conditions
Chronic Kidney DiseasesHyperphosphatemia
Interventions
DRUG

AP-306

A blood phosphorus lowering drug with a novel mechanism

DRUG

Sevelamer Carbonate

A phosphate binder

Trial Locations (1)

610072

Sichuan Provincial People's Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Alebund Pharmaceuticals

INDUSTRY

NCT05764590 - A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients | Biotech Hunter | Biotech Hunter